




The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is 161%, being 91% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	326,820
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	56,163
Liabilities, Non-Current	5,992
Other Assets	58,082
Other Compr. Net Income	252
Other Expenses	47,144
Other Liabilities	358,883
Other Net Income	-36,434
Other Revenues	307,711
Property and Equipment	47,463
Research and Development	268,461
Selling, General and Administrative Expense	52,364

Output Variable	Value in 1000 USD
Assets	508,866
Liabilities	421,038
Expenses	367,969
Revenues	307,711
Stockholders Equity	87,828
Net Income	-96,692
Comprehensive Net Income	-96,566
BaseVar	821,135
ECR before LimitedLiability	20%
Economic Capital Ratio	161%